JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Pathogenesis, Diagnosis, and Management of Urolithiasis

Rutu V Naik*[1], Santosh B Patil[2]

[1] *Research Scholar, Department of Pharmacology, KLE College of Pharmacy, Hubballi, Karnataka, India*
[2] *Assistant Professor, Department of Pharmacology, KLE College of Pharmacy, Hubballi, Karnataka, India*

Publication history: Received on 20th Mar 2025; Revised on 7th April 2025; Accepted on 15th April 2025

Article DOI: 10.69613/n6jbn006

Abstract: Urolithiasis is characterized by the formation of solid mineral deposits within the urinary tract. The condition arises due to interactions between metabolic, environmental, and genetic factors that promote crystal nucleation, growth, and retention. Recent studies indicate rising prevalence rates worldwide, particularly in industrialized nations, with approximately 10% annual recurrence in the first year and up to 75% by 20 years post-initial episode. The pathophysiology involves multiple stages, beginning with urinary supersaturation of stone-forming minerals, followed by crystal nucleation, growth, aggregation, and retention within the renal system. Various intrinsic and extrinsic factors influence stone formation, including urinary pH, hypocitraturia, hyperoxaluria, and hyperuricosuria. The most prevalent stone type remains calcium oxalate (70-80%), followed by calcium phosphate, uric acid, struvite, and cystine stones. Risk factors encompass demographic variables, climate conditions, dietary habits, and comorbid conditions such as obesity, diabetes, and metabolic syndrome. Modern diagnostic techniques incorporate clinical assessment, biochemical analysis, and advanced imaging techniques, enabling precise stone characterization and localization.

Keywords: Urolithiasis; Crystal Formation; Stone Types; Risk Factors; Diagnostic Imaging.

1. Introduction

Urolithiasis, derived from Greek terms "ouron" (urine), "oros" (flow), and "lithos" (stone), represents the formation of solid mineral concretions within the urinary system [1]. This condition manifests as a complex pathological process involving the deposition of various crystalline compounds, predominantly composed of calcium, oxalate, and phosphate minerals [2]. The global prevalence of urolithiasis has shown a steady increase over recent decades, with current estimates indicating that 10-12% of the population will experience at least one stone episode during their lifetime [3]. The significance of urolithiasis extends beyond its primary manifestation, as it frequently presents with complications such as urinary tract obstruction, infection, and renal dysfunction [4]. Epidemiological studies reveal marked geographical variations in prevalence rates, with higher incidences reported in regions characterized by warm climates and westernized dietary patterns [5].

The condition shows a notable gender disparity, affecting approximately 12% of men compared to 6% of women, with peak incidence occurring between ages 20-40 years [6]. The formation of urinary stones involves intricate physicochemical processes influenced by multiple factors, including urinary supersaturation, crystal nucleation, growth, and retention within the urinary tract [7]. These processes are modulated by various intrinsic and extrinsic factors, ranging from genetic predisposition to environmental influences [8]. The composition of urinary stones varies, with calcium oxalate stones representing 70-80% of cases, followed by calcium phosphate, uric acid, struvite, and cystine stones [9]. Recent advances in molecular biology and imaging techniques have enhanced our understanding of stone formation mechanisms and improved diagnostic capabilities [10]. However, the high recurrence rates, approximately 50% within 5-10 years of initial episode, highlight the need for continued research and improved preventive strategies [11].

2. Pathophysiology

2.1. Fundamental Mechanisms

The formation of urinary stones occurs through a series of sequential physicochemical events that transform dissolved urinary solutes into solid crystalline structures [12]. This process involves four primary stages: urinary supersaturation, crystal nucleation, crystal growth, and crystal aggregation [13].

* Corresponding author: Rutu V Naik

2.1.1. Urinary Supersaturation

Urinary supersaturation represents the initial and crucial step in stone formation, occurring when the concentration of stone-forming constituents exceeds their solubility threshold in urine [14]. This state creates thermodynamically unstable conditions that favor crystal formation [15]. The degree of supersaturation varies with urinary pH, temperature, and the presence of various ions and molecules that can either promote or inhibit crystal formation [16].



Figure 1. Pathophysiology of Urinary Stone Formation

2.1.2. Crystal Nucleation

Following supersaturation, crystal nucleation marks the beginning of solid phase formation from solution [17]. This process can occur through homogeneous nucleation, where crystals form spontaneously in solution, or heterogeneous nucleation, which involves crystal formation on pre-existing surfaces such as cellular debris or other crystals [18]. The energy barrier for heterogeneous nucleation is typically lower, making it the predominant mechanism in biological systems [19]

2.1.3. Crystal Growth and Aggregation

Once nucleation occurs, crystals expand through the ordered addition of constituent ions to their surfaces [20]. The rate of crystal growth depends on multiple factors, including the degree of supersaturation, urinary pH, and the presence of growth modulators [21]. Growth inhibitors, such as citrate and magnesium, interact with crystal surfaces to prevent further expansion, while promoters like calcium and oxalate enhance crystal development [22].

Crystal aggregation involves the combination of individual crystals into larger masses [23]. This process proves particularly significant in stone formation as it accelerates the development of clinically relevant concretions. The aggregation process depends on surface charge interactions, with urinary macromolecules playing crucial roles in either promoting or inhibiting this stage [24].

2.2. Urinary Factors Affecting Stone Formation

2.2.1. Urinary pH

The pH of urine significantly influences stone formation by affecting the solubility of various minerals [25]. Acidic urine (pH <5.5) promotes uric acid stone formation, while alkaline conditions (pH >6.8) favor calcium phosphate precipitation [26]. Research indicates that individuals with higher body mass index tend to have more acidic urine, potentially explaining the association between obesity and increased stone risk [27].

2.2.2. Hypocitraturia

Citrate serves as a crucial inhibitor of stone formation through multiple mechanisms [28]. Normal urinary citrate excretion exceeds 320 mg per day, with lower levels defining hypocitraturia [29]. Citrate forms soluble complexes with calcium, reducing free calcium ion concentration and inhibiting calcium crystal formation and aggregation [30]. Various conditions, including metabolic acidosis, hypokalemia, and certain dietary patterns, can reduce urinary citrate excretion [31].

2.2.3. Hyperoxaluria

Elevated urinary oxalate excretion significantly increases the risk of calcium oxalate stone formation [32]. Normal oxalate excretion typically remains below 45 mg per day, with higher levels indicating hyperoxaluria [33]. Both genetic factors affecting oxalate metabolism and dietary sources contribute to hyperoxaluria [34]. The condition particularly affects stone formation risk when combined with inadequate dietary calcium intake, as calcium normally binds oxalate in the gastrointestinal tract, limiting its absorption [35].

2.2.4. Hyperuricosuria

Excessive urinary uric acid excretion promotes stone formation through multiple mechanisms [36]. While the precise relationship between hyperuricosuria and calcium oxalate stone formation remains under investigation, evidence suggests that uric acid crystals may serve as nucleation sites for calcium oxalate stone development [37]. Additionally, elevated uric acid levels can lead to the formation of sodium hydrogen urate crystals, further complicating stone pathogenesis [38].

3. Types of Urolithiasis

3.1. Calcium oxalate stone

Calcium oxalate stones represent the most prevalent form of urinary calculi, accounting for approximately 70-80% of all cases [39]. These stones exist in two primary crystalline forms: calcium oxalate monohydrate (COM) and calcium oxalate dihydrate (COD) [40]. COM crystals typically present as thin, plate-like structures with characteristic "dumbbell" morphology, while COD crystals exhibit distinctive tetragonal bipyramidal shapes [41]. The formation of these stones involves complex interactions between calcium and oxalate ions, influenced by various urinary conditions and the presence of modulatory substances [42].

Table 1. Classification of Urinary Calculi and Their Characteristics

Stone Type	Prevalence (%)	Chemical Composition	Characteristics	Risk Factors
Calcium Oxalate	70-80	$CaC_2O_4 \cdot H_2O$ (COM) $CaC_2O_4 \cdot 2H_2O$ (COD)	Radiopaque, brown/black color	Hypercalciuria, Hyperoxaluria, Low urine volume
Calcium Phosphate	10-20	$Ca_5(PO_4)_3(OH)$ $Ca_3(PO_4)_2$	Radiopaque, white/gray color	Alkaline urine, Primary hyperparathyroidism
Uric Acid	5-10	$C_5H_4N_4O_3$	Radiolucent, yellow/reddish	Acidic urine, Hyperuricosuria, Gout
Struvite	7-8	$MgNH_4PO_4 \cdot 6H_2O$	Radiopaque, white/gray	UTI with urease-producing bacteria
Cystine	1-2	$[-SCH_2CH(NH_2)COOH]_2$	Moderately radiopaque, yellow	Genetic disorder (cystinuria)

3.2. Calcium Phosphate Stones

Comprising 10-20% of urinary calculi, calcium phosphate stones manifest in three primary mineralogical forms [43]:

- Tricalcium phosphate (whitlockite)
- Calcium hydrogen phosphate dihydrate (brushite)
- Basic calcium phosphate (apatite)

The formation of these stones strongly correlates with elevated urinary pH, typically above 6.8, along with hypocitraturia and hypercalciuria [44]. The conversion between different calcium phosphate phases depends on local ionic concentrations and pH conditions, with brushite often serving as a precursor to more stable hydroxyapatite formations [45].

3.3. Uric Acid Stones

Uric acid stones constitute approximately 10% of all urinary calculi and present unique challenges in diagnosis due to their radiolucent nature [46]. Their formation primarily results from persistently acidic urine (pH <5.5) combined with hyperuricosuria [47]. These stones typically exhibit a distinctive internal structure, characterized by concentrically layered, pebble-like masses with a core of loosely packed anhydrous uric acid crystals surrounded by radiating columnar formations [48].

3.4. Struvite Stones

Also known as "infection stones," struvite (magnesium ammonium phosphate) stones develop in response to urinary tract infections with urease-producing organisms [49]. These stones comprise 7-8% of all urinary calculi and show higher prevalence in females [50]. The pathogenic mechanism involves bacterial urease hydrolyzing urea, leading to increased urinary pH and ammonia production, which creates optimal conditions for struvite crystal formation [51]. These stones often grow rapidly, potentially forming large "staghorn" calculi that can occupy the entire renal collecting system [52].

3.5. Cystine Stones

Cystine stones, though rare (1-2% of all cases), represent a significant clinical challenge due to their hereditary nature and resistance to conventional treatments [53]. These stones result from cystinuria, a genetic disorder affecting cystine transport in the kidneys and intestine [54]. The characteristic hexagonal crystals form in acidic urine when cystine concentration exceeds its solubility threshold, typically around 250 mg/L [55]. Their management requires dietary modification, urinary alkalinization, and specific pharmacological interventions [56].

4. Risk Factors for Urolilthiasis

4.1. Demographic Factors

4.1.1. Age, Gender, and Race

Age-related variations in stone formation show distinct patterns, with prevalence rates of 0.58% in individuals under 45 years increasing to 4.7% in those over 65 years [57]. Gender differences manifest prominently, with males showing higher susceptibility, attributed partly to hormonal influences and metabolic differences [58]. Racial disparities in stone formation indicate varying prevalence rates among different ethnic groups, though these differences may reflect environmental and dietary factors rather than purely genetic influences [59].

4.1.2. Genetic Predisposition

Approximately 25% of patients with urolithiasis report a positive family history, suggesting significant genetic components in stone formation [60]. Genetic factors particularly influence specific stone types, such as cystine stones and certain forms of calcium oxalate stones [61]. Studies indicate that about 70% of patients with renal tubular acidosis, a condition strongly associated with stone formation, demonstrate genetic components [62].

Table 3. Risk Stratification for Stone Recurrence

Risk Level	Clinical Features	Metabolic Abnormalities	Recommended Follow-up
Low	Single stone episode No family history Normal metabolic evaluation	None or minimal	Annual follow-up Basic dietary modifications
Moderate	1-2 stones/year Limited metabolic abnormalities	Single metabolic disorder	Bi-annual metabolic evaluation Specific dietary interventions
High	>2 stones/year Multiple or bilateral stones Anatomical abnormalities	Multiple metabolic disorders	Quarterly evaluation Medical therapy Dietary restrictions
Very High	Genetic disorders Complete staghorn calculi Recurrent UTIs	Complex metabolic disorders	Monthly monitoring Intensive medical management Surgical intervention

4.2. Environmental Factors

4.2.1. Climate and Seasonal Variations

Stone formation shows marked seasonal patterns, with higher incidence during warmer months [63]. This correlation stems from multiple factors:

- Increased perspiration leading to concentrated urine
- Reduced fluid intake resulting in lower urinary volume
- Enhanced vitamin D synthesis due to sun exposure
- Dehydration risk in hot climates [64]

4.2.2. Regional Variations

Regional variations in stone prevalence correlate with climate patterns, urbanization levels, and dietary habits [65]. Areas with high ambient temperatures and significant sunlight exposure typically show elevated stone formation rates, particularly in regions characterized by westernized dietary patterns [66].

4.3. Dietary Factors

4.3.1. Nutritional Factors

Dietary composition significantly impacts stone formation risk through multiple mechanisms [67]. High protein consumption, particularly animal protein, increases urinary calcium excretion and reduces urinary pH [68]. Excessive sodium intake enhances calcium excretion and reduces citrate levels in urine [69]. Studies demonstrate correlations between stone formation and:

- High caloric intake
- Elevated protein consumption
- Excessive salt intake
- Inadequate fluid consumption [70]

Table 4. Dietary Recommendations for Stone Prevention

Dietary Factor	Recommendation	Rationale	Stone Type Affected
Fluid Intake	>2.5-3 L/day	Reduces urinary supersaturation	All types
Sodium	<2300 mg/day	Reduces calcium excretion	Calcium stones
Animal Protein	0.8-1.0 g/kg/day	Reduces acid load and calcium excretion	Calcium and uric acid
Calcium	1000-1200 mg/day	Binds dietary oxalate	Calcium oxalate
Oxalate	<100 mg/day	Reduces calcium oxalate formation	Calcium oxalate
Citrus Fruits	1-2 servings/day	Increases urinary citrate	Calcium stones
Potassium	>3500 mg/day	Alkalinizes urine	Uric acid

4.3.2. Fluid Intake

Fluid intake patterns directly influence urinary concentration and volume, critical factors in stone formation [71]. Low fluid intake results in concentrated urine, promoting crystal formation and aggregation. The timing and type of fluid consumption also affect stone risk, with certain beverages showing protective or promotional effects on stone formation [72].

4.4. Comorbidities

4.4.1. Metabolic Conditions

Several metabolic disorders increase stone formation risk:

- Obesity correlates with increased uric acid and calcium oxalate stone formation [73]
- Diabetes mellitus affects urinary pH and increases stone risk [74]
- Metabolic syndrome components contribute to stone formation through multiple pathways [75]

4.4.2. Cardiovascular and Renal Conditions

Hypertension demonstrates a significant association with increased stone formation, potentially through alterations in calcium metabolism and renal tubular function [76]. Chronic kidney disease affects mineral metabolism and urinary composition, potentially increasing stone risk through multiple mechanisms [77]. The relationship between cardiovascular disease and stone formation appears bidirectional, with shared risk factors and pathogenic mechanisms [78].

4.4.3. Gastrointestinal Disorders

Inflammatory bowel disease, particularly Crohn's disease and ulcerative colitis, increases stone risk through altered mineral absorption and changes in urinary composition [79]. Bariatric surgery patients show elevated stone risk due to altered mineral metabolism and increased oxalate absorption [80]. Chronic diarrheal conditions can lead to fluid losses and metabolic changes that promote stone formation [81].



Figure 2. Stone Management Algorithm

5. Diagnosis

5.1. Clinical Assessment

5.1.1. Patient History

A detailed patient history forms the cornerstone of urolithiasis diagnosis and management. Clinicians must carefully document the characteristics and frequency of stone episodes, including the nature and severity of pain, associated symptoms, and previous stone events. Family history provides valuable insights into genetic predisposition and inherited metabolic disorders. Detailed dietary assessment, including fluid intake patterns, specific food preferences, and dietary restrictions, helps identify modifiable risk factors. The evaluation of associated medical conditions, particularly metabolic disorders and systemic diseases, contributes to understanding the underlying etiology. Additionally, a thorough medication review is essential, as certain pharmaceuticals may influence stone formation through various mechanisms [82]



Figure 2. Diagnostic Approach to Urolithiasis

5.1.2. Physical Examination

The physical examination in patients with suspected urolithiasis requires systematic evaluation of specific signs and symptoms. Costovertebral angle tenderness, a classic finding, often indicates renal involvement and helps localize the stone. Careful assessment of abdominal pain patterns aids in differentiating stone pain from other abdominal pathologies. Physicians must identify signs of urinary obstruction, including bladder distention and associated complications. The examination should also focus on detecting evidence of systemic conditions that may contribute to stone formation, such as gout tophi, metabolic syndrome manifestations, or signs of endocrine disorders [83]

5.2. Laboratory Investigations

5.2.1. Urinalysis

Urinalysis serves as a fundamental diagnostic tool in the evaluation of urolithiasis. The examination includes microscopic analysis for crystal identification and characterization, providing crucial information about stone composition and formation tendencies. Accurate pH measurement helps determine the risk of specific stone types and guides therapeutic interventions. Specific gravity determination offers insights into urinary concentration and hydration status. The presence of infection markers suggests potential infectious components in stone formation, while hematuria evaluation helps confirm urinary tract involvement and may indicate ongoing stone activity [84]

Table 2. 24-Hour Urine Parameters and Their Clinical Significance

Parameter	Normal Range	Clinical Significance	Associated Stone Type
Volume	>2.5 L/day	Low volume increases supersaturation	All types
Calcium	<250 mg/day (men) <200 mg/day (women)	Hypercalciuria increases stone risk	Calcium stones
Oxalate	<45 mg/day	Hyperoxaluria promotes CaOx stones	Calcium oxalate
Citrate	>320 mg/day	Inhibitor of calcium stone formation	Calcium stones
pH	5.5-6.5	Influences crystal formation	Uric acid (<5.5) Calcium phosphate (>6.8)
Uric Acid	<800 mg/day (men) <750 mg/day (women)	Promotes uric acid stones	Uric acid

5.2.2. Blood Chemistry

Blood chemistry analysis provides essential information about systemic factors contributing to stone formation. Serum calcium and phosphate measurements help identify disorders of mineral metabolism. Comprehensive kidney function parameters, including creatinine and blood urea nitrogen, assess renal impact and function. Uric acid levels contribute to understanding the risk of uric acid stone formation. Electrolyte balance evaluation helps detect underlying metabolic abnormalities, while specific markers aid in identifying metabolic disorders that may contribute to stone formation [85]

5.2.3. 24-Hour Urine Collection

The 24-hour urine collection represents a crucial component in the metabolic evaluation of stone formers. This comprehensive assessment measures the daily excretion of stone-forming substances, including calcium, oxalate, citrate, and uric acid. Analysis of urinary volume patterns throughout the day helps identify periods of increased risk. Citrate and other inhibitor levels provide information about natural stone prevention mechanisms. The overall stone risk assessment derived from this collection guides individualized prevention strategies and therapeutic interventions [86]

5.3. Imaging Techniques

5.3.1. Conventional Radiography

Plain radiography, specifically the KUB (Kidney, Ureter, Bladder) view, serves as an initial imaging modality in urolithiasis evaluation. This technique effectively screens for radiopaque stones, particularly those containing calcium. The imaging allows accurate assessment of stone size and location, crucial information for treatment planning. Additionally, KUB radiography provides a cost-effective method for follow-up evaluation of known stones, enabling monitoring of stone progression or resolution [87]

5.3.2. Ultrasonography

Ultrasonography offers significant advantages in stone disease evaluation through its non-invasive nature and absence of radiation exposure. This imaging modality enables reliable stone detection, particularly in the kidneys and proximal ureters. The real-time nature of ultrasound examination allows detailed evaluation of kidney structure and architecture. Assessment of hydronephrosis helps determine the degree of obstruction and urgency of intervention. The technique proves particularly valuable in monitoring pregnant patients and those requiring frequent follow-up examinations [88]

5.3.3. Computed Tomography

Non-contrast computed tomography has emerged as the gold standard in urolithiasis imaging, offering superior diagnostic capabilities. This modality provides exceptionally precise stone location and size measurements, critical for treatment planning. The ability to determine stone density helps predict treatment success and guides intervention selection. Detailed assessment of surrounding anatomy aids in identifying anatomical variations and potential complications. The high sensitivity and specificity of CT scanning make it particularly valuable in emergency settings and complex cases [89, 90]

Table 5. Imaging Methods for Urolithiasis

Imaging Method	Sensitivity (%)	Specificity (%)	Advantages	Limitations
CT (non-contrast)	95-98	96-98	Gold standard Accurate size/density No contrast needed	Radiation exposure Cost
Ultrasound	45-85	80-95	No radiation Real-time imaging Affordable	Operator dependent Limited for small stones
KUB X-ray	45-60	75-85	Low-cost Quick screening	Limited to radiopaque stones Poor soft tissue detail
MRI	82-85	88-90	No radiation Good soft tissue detail	Cost Limited stone detection
Digital Tomosynthesis	86-90	90-92	Lower radiation than CT Better than KUB	Limited availability Cost

6. Conclusion

Recent advances in molecular biology and imaging technologies have improved our knowledge of stone formation processes and improved diagnostic capabilities. The increasing global prevalence of urolithiasis, coupled with high recurrence rates, emphasizes the importance of preventive strategies and early intervention. The identification of modifiable risk factors provides opportunities for targeted interventions, particularly in dietary modifications and lifestyle changes. The role of medical comorbidities in stone formation highlights the need for comprehensive patient evaluation and management strategies that address both primary stone disease and associated conditions. Modern diagnostic approaches, combining detailed metabolic evaluation with advanced imaging techniques, enable precise characterization of stone disease and guide therapeutic decisions. The advent of new therapeutic approaches and improved understanding of genetic factors may lead to more effective interventions for both prevention and treatment. Integration of artificial intelligence and machine learning technologies in diagnostic imaging and risk prediction represents a promising avenue for advancing urolithiasis care.

References

[1] Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol. 2014;27(3):241-245.

[2] Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324.

[3] Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165.

[4] Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954-963.

[5] Sorokin I, Mamoulakis C, Miyazawa K, et al. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301-1320.

[6] Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008.

[7] Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12(9):519-533.

[8] Ferraro PM, Curhan GC, D'Addessi A, et al. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol. 2017;30(2):227-233.

[9] Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25(5):831-841.

[10] Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-662.

[11] Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011;6(8):2069-2075.

[12] Ratkalkar VN, Kleinman JG. Mechanisms of stone formation. Clin Rev Bone Miner Metab. 2011;9(3-4):187-197.

[13] Aggarwal KP, Narula S, Kakkar M, et al. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013;2013:292953.

[14] Daudon M, Bazin D, Letavernier E. Randall's plaque as the origin of calcium oxalate kidney stones. Urolithiasis. 2015;43(1):5-11.

[15] Evan AP, Lingeman JE, Coe FL, et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005;67(2):576-591.

[16] Evan AP, Worcester EM, Coe FL, et al. Mechanisms of human kidney stone formation. Urolithiasis. 2015;43(1):19-32.

[17] Thongboonkerd V. Proteomics of crystal-cell interactions: a model for kidney stone research. Cells. 2019;8(9):1076.

[18] Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol. 2014;3(3):256-276.

[19] Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-543.

[20] Goldfarb DS. A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol. 2012;7(7):1172-1178.

[21] Daudon M, Frochot V, Bazin D, et al. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163-201.

[22] Abou Chakra M, Dellis AE, Papatsoris AG, et al. Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium. Expert Opin Pharmacother. 2020;21(1):85-96.

[23] Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-e96.

[24] Ratkalkar VN, Kleinman JG. Mechanisms of stone formation. Clin Rev Bone Miner Metab. 2011;9(3-4):187-197.

[25] Maalouf NM. Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr. 2011;21(1):128-131.

[26] Sakhaee K, Maalouf NM, Sinnott B. Clinical review: Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847-1860.

[27] Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis. 2006;48(6):905-915.

[28] Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009;11(3):134-144.

[29] Eisner BH, Porten SP, Bechis SK, et al. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010;183(6):2244-2248.

[30] Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120-132.

[31] Pak CY. Medical management of urinary stone disease. Nephron Clin Pract. 2004;98(2):c49-c53.

[32] Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001;59(1):270-276.

[33] Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264-1271.

[34] Knight J, Holmes RP, Assimos DG. Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urolithiasis. 2016;44(4):333-342.

[35] Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126(7):497-504.

[36] Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008;28(2):174-180.

[37] Grases F, Costa-Bauza A, Prieto RM. Renal lithiasis and nutrition. Nutr J. 2006;5:23.

[38] Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: a systemic metabolic disorder. Clin Rev Bone Miner Metab. 2011;9(3-4):207-217.

[39] Evan AP, Lingeman JE, Coe FL, et al. Randall's plaque of calcium oxalate origin: proof of concept. J Urol. 2009;181(3):1368-1374.

[40] Williams JC Jr, Worcester E, Lingeman JE. What can the microstructure of stones tell us? Urolithiasis. 2017;45(1):19-25.

[41] Daudon M, Dessombz A, Frochot V, et al. Comprehensive morpho-constitutional analysis of urinary stones improves etiological diagnosis and therapeutic strategy of nephrolithiasis. C R Chim. 2016;19(11-12):1470-1491.

[42] Khan SR. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res. 1995;23(2):71-79.

[43] Evan AP, Lingeman JE, Worcester EM, et al. Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones. Anat Rec. 2014;297(4):731-748.

[44] Parks JH, Worcester EM, Coe FL, et al. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004;66(2):777-785.

[45] Daudon M, Bazin D, Letavernier E. Randall's plaque as the origin of calcium oxalate kidney stones. Urolithiasis. 2015;43(Suppl 1):5-11.

[46] Maalouf NM. Uric acid rocks: an update on uric acid nephrolithiasis. Adv Chronic Kidney Dis. 2019;26(2):116-122.

[47] Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75(6):585-595.

[48] Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115(10):2598-2608.

[49] Bichler KH, Eipper E, Naber K, et al. Urinary infection stones. Int J Antimicrob Agents. 2002;19(6):488-498.

[50] Flannigan R, Choy WH, Chew B, et al. Renal struvite stones—pathogenesis, microbiology, and management strategies. Nat Rev Urol. 2014;11(6):333-341.

[51] McLean RJC, Nickel JC, Cheng KJ, et al. The ecology and pathogenicity of urease-producing bacteria in the urinary tract. Crit Rev Microbiol. 1988;16(1):37-79.

[52] Preminger GM, Assimos DG, Lingeman JE, et al. AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol. 2005;173(6):1991-2000.

[53] Biyani CS, Cartledge JJ. Cystinuria—diagnosis and management. EAU-EBU Update Series. 2006;4(5):175-183.

[54] Sahota A, Tischfield JA, Goldfarb DS, et al. Cystinuria: genetic aspects, mouse models, and a new approach to therapy. Urolithiasis. 2019;47(1):57-66.

[55] Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol. 2008;28(2):181-191.

[56] Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333-344.

[57] Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455-462.

[58] Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender prevalence of stone disease. J Urol. 2007;177(3):979-982.

[59] Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int. 1994;46(3):893-899.

[60] Resnick M, Pridgen DB, Goodman HO. Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med. 1968;278(24):1313-1318.

[61] Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009;41(8):926-930.

[62] Mohebbi N, Wagner CA. Pathophysiology, diagnosis and treatment of inherited distal renal tubular acidosis. J Nephrol. 2018;31(4):511-522.

[63] Fakheri RJ, Goldfarb DS. Ambient temperature as a contributor to kidney stone formation: implications of global warming. Kidney Int. 2011;79(11):1178-1185.

[64] Tasian GE, Copelovitch L. Evaluation and medical management of kidney stones in children. J Urol. 2014;192(5):1329-1336.

[65] Robertson WG. Stone formation in the Middle Eastern Gulf States: a review. Arab J Urol. 2012;10(3):265-272.

[66] Scales CD Jr, Tasian GE, Schwaderer AL, et al. Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol. 2016;11(7):1305-1312.

[67] Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009;20(10):2253-2259.

[68] Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77-84.

[69] Nouvenne A, Meschi T, Prati B, et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am J Clin Nutr. 2010;91(3):565-570.

[70] Ferraro PM, Taylor EN, Gambaro G, Curhan GC. Dietary and lifestyle risk factors associated with incident kidney stones in men and women. J Urol. 2017;198(4):858-863.

[71] Qaseem A, Dallas P, Forciea MA, et al. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659-667.

[72] Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int. 2013;84(1):45-53.

[73] Semins MJ, Shore AD, Makary MA, et al. The association of increasing body mass index and kidney stone disease. J Urol. 2010;183(2):571-575.

[74] Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68(3):1230-1235.

[75] Wong YV, Cook P, Somani BK. The association of metabolic syndrome and urolithiasis. Int J Endocrinol. 2015;2015:570674.

[76] Ferraro PM, Taylor EN, Eisner BH, et al. History of kidney stones and the risk of coronary heart disease. JAMA. 2013;310(4):408-415.

[77] Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol. 2010;21(10):1641-1644.

[78] Alexander RT, Hemmelgarn BR, Wiebe N, et al. Kidney stones and kidney function loss: a cohort study. BMJ. 2012;345:e5287.

[79] Gaspar SR, Mendonça T, Oliveira P, et al. Urolithiasis and inflammatory bowel disease. Urol Int. 2016;96(3):249-254.

[80] Bhatti UH, Duffy AJ, Roberts KE, et al. Nephrolithiasis after bariatric surgery: A review of pathophysiologic mechanisms and procedural risk. Int J Surg. 2016;36(Pt D):618-623

[81] Goldfarb DS, Zisman AL. Genetic causes of kidney stones and chronic kidney disease. Kidney Int. 2019;95(4):787-789.

[82] Pearle MS, Lotan Y. Urinary lithiasis: etiology, epidemiology, and pathogenesis. In: Campbell-Walsh Urology. 11th ed. Philadelphia, PA: Elsevier; 2016:1170-1199.

[83] Sorensen MD, Chi T, Shara NM, et al. Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the Women's Health Initiative. J Am Soc Nephrol. 2014;25(2):362-369.

[84] Gul Z, Monga M. Medical and dietary therapy for kidney stone prevention. Korean J Urol. 2014;55(12):775-779.

[85] Morgan MSC, Pearle MS. Medical management of renal stones. BMJ. 2016;352:i52.

[86] Gambaro G, Croppi E, Coe F, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016;29(6):715-734.

[87] Smith-Bindman R, Aubin C, Bailitz J, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100-1110.

[88] Ferraro PM, Gambaro G. Calcium nephrolithiasis, metabolic syndrome and the cardiovascular risk. Nephrol Dial Transplant. 2019;34(8):1266-1271.

[89] Letavernier E, Daudon M. Vitamin D, hypercalciuria and kidney stones. Nutrients. 2018;10(3):366.

[90] Trinchieri A, Montanari E. Biochemical and dietary risk factors for nephrolithiasis: state of the art and future perspectives. J Nephrol. 2017;30(6):735-747.